KERYX BIOPHARMACEUTICALS INCORPORATED (NASDAQ: KERX) "Up 17.68% in morning trading"
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease and cancer. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing KRX-0401 (perifosine), which is in Phase 3 clinical development for multiple myeloma. Keryx is headquartered in New York City.
ARENA PHARMACEUTICALS INCORPORATED (NASDAQ: ARNA) "Up 57.60% in morning trading"
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company’s advanced stage drug candidate includes the lorcaserin for the treatment of weight management, including weight loss and maintenance of weight loss. Its product in clinical development comprises APD811, which is under Phase I clinical trial for the treatment of pulmonary arterial hypertension. The company’s preclinical development programs include APD334, an oral treatment for the treatment of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis; and APD371 for the treatment of pain. The company also researches and develops GPR119, a pharmaceutical target for discovering orally available small molecule agonists for the treatment of type 2 diabetes, as well as temanogrel, nelotanserin, and earlier-stage programs. In addition, the company provides manufacturing services. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
BEBIDA BEVERAGE COMPANY (OTC: BBDA) "Up 25.00% in morning trading"
BeBevCo (Bebida Beverage Company) develops, manufactures and markets beverages including Koma Unwind "Chillaxation Drink™," Koma Unwind Sugar-free "Chillaxation Drink™," and Koma Unwind "Chillaxation Shot™" as well as Potencia Energy Drink, Potencia "BLAST" energy shot and Piranha Water.
DC BRANDS INTERNATIONAL INCORPORATED (OTC: HRDN) "Up 60.00% in morning trading"
DC Brands International, a publicly traded company under the ticker symbol (HRDN), presently specializes in the manufacturing of its functional beverages and health products. Established in 1998, DC Brands began producing a number of lines of energy drinks in 2005. DC Brands then purchased the assets of H.A.R.D. Nutrition and began its quest to produce a new health line of products. DC Brands has recently announced the release of its new H.A.R.D. Nutrition Functional Water Systems, which it expects will revolutionize the functional beverage category.
About OTCPicks.com
OTCPicks.com, one of the leading penny stock Web sites, presents its daily Stocks to Watch and Midday Market Movers every weekday. In addition to all the latest penny stock news, OTCPicks also offers daily newsletters, unique commentaries and free profiles, alerts and investing tips.
The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily stock alerts go to www.otcpicks.com to sign up.
Disclosure: OTCPicks.com and affiliates have been not been compensated by any of the companies covered in this release.
